Compare CXDO & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXDO | ENLV |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 258.7M |
| IPO Year | 1999 | 2014 |
| Metric | CXDO | ENLV |
|---|---|---|
| Price | $6.19 | $0.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $9.25 | ★ $13.00 |
| AVG Volume (30 Days) | 186.1K | ★ 565.3K |
| Earning Date | 05-05-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 166.67 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $68,167,000.00 | N/A |
| Revenue This Year | $38.52 | N/A |
| Revenue Next Year | $19.22 | N/A |
| P/E Ratio | $38.88 | ★ N/A |
| Revenue Growth | ★ 12.05 | N/A |
| 52 Week Low | $3.75 | $0.66 |
| 52 Week High | $7.80 | $2.10 |
| Indicator | CXDO | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 39.97 |
| Support Level | $6.08 | $0.81 |
| Resistance Level | $6.73 | $1.25 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 31.38 | 10.72 |
Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.